CA19-9 Benefits Prognostication of Pancreatic Cancer: Is It Time to Add CA19-9 to Its Staging Criteria? | Ann Surg Oncol;31(8): 4839-4840, 2024 Aug. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

CA19-9 Benefits Prognostication of Pancreatic Cancer: Is It Time to Add CA19-9 to Its Staging Criteria?

Gao, Xiang; In, Haejin.

Affiliation

Gao X; Division of Surgical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
In H; Division of Surgical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA. hi80@cinj.rutgers.edu.

Ann Surg Oncol ; 31(8): 4839-4840, 2024 Aug.

Article in En | MEDLINE | ID: mdl-38709364

Subject(s)

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pancreatic Neoplasms / CA-19-9 Antigen / Neoplasm Staging Limits: Humans Language: En Journal: Ann Surg Oncol / Ann. surg. oncol / Annals of surgical oncology Journal subject: NEOPLASIAS Year: 2024 Document type: Article Affiliation country: Country of publication:

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pancreatic Neoplasms / CA-19-9 Antigen / Neoplasm Staging Limits: Humans Language: En Journal: Ann Surg Oncol / Ann. surg. oncol / Annals of surgical oncology Journal subject: NEOPLASIAS Year: 2024 Document type: Article Affiliation country: Country of publication: